Lapatinib-induced hepatitis: A case report

doi:10.3748/wjg.v17.i18.2349

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 17, Issue 18

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (3109)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-1) series, Tables (1-1) series.

Item

Count

PDF

337

HTML

2506

Figures (1-1)

151

Tables (1-1)

115

Sum=3109

May 14, 2011 (publication date) through Apr 28, 2024

Times Cited of This Article

Times Cited (25)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Case Report

World J Gastroenterol. May 14, 2011; 17(18): 2349-2352
Published online May 14, 2011. doi: 10.3748/wjg.v17.i18.2349

Lapatinib-induced hepatitis: A case report

Stavros Peroukides, Thomas Makatsoris, Angelos Koutras, Athanasios Tsamandas, Adimchi Onyenadum, Chryssoula Labropoulou-Karatza, Haralabos Kalofonos

Stavros Peroukides, Thomas Makatsoris, Angelos Koutras, Adimchi Onyenadum, Haralabos Kalofonos, Department of Medical Oncology, University Hospital of Patras, 26500 Rio, Patras, Greece

Athanasios Tsamandas, Department of Pathology, University Hospital of Patras, 26500 Rio, Patras, Greece

Chryssoula Labropoulou-Karatza, Department of Internal Medicine, University Hospital of Patras, 26500 Rio, Patras, Greece

Author contributions: Peroukides S, Makatsoris T, Koutras A, Onyenadum A and Kalofonos H cured the patient and wrote the paper; Tsamandas A and Labropoulou-Karatza C confirmed the pathologic diagnosis.

Correspondence to: Stavros Peroukides, MD, MSc, PhD, Department of Medical Oncology, School of Medicine, University of Patras, 26500 Rio, Patras, Greece. panio@upatras.gr

Telephone: +30-2610-999535 Fax: +30-2610-994645

Received: August 16, 2010
Revised: September 16, 2010
Accepted: September 23, 2010
Published online: May 14, 2011

Abstract

Lapatinib is an inhibitor of the tyrosine kinases of human epidermal growth factor receptor type 2 (HER2) and epidermal growth factor receptor type 1, with clinical activity in HER2-positive metastatic breast cancer. We present here a 60 year-old patient with metastatic breast cancer who presented with jaundice and increased serum aminotransferase levels and who had been treated with lapatinib for the previous 14 days. Laboratory tests excluded other causes of acute liver injury. Liver biopsy revealed lesions compatible with drug-induced hepatotoxicity. Bilirubin and liver enzymes returned to normal within three months of lapatinib discontinuation. Lapatinib should be included among the causes of drug-induced hepatitis.

Keywords: Lapatinib, Hepatitis, Hepatotoxicity, Breast cancer, Human epidermal growth factor receptor type 2